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Abstract 
Magnetic drug targeting has been proposed as means of concentrating therapeutic agents at a 
target site and the success of this approach has been demonstrated in a number of studies. 
However, the behavior of magnetic carriers in blood vessels and tumor microcirculation still 
remains unclear. In this work, we utilized polymeric magnetic nanocapsules (m-NCs) for 
magnetic targeting in tumors and dynamically visualized them within blood vessels and 
tumor tissues before, during and after magnetic field exposure using fibered confocal 
fluorescence microscopy (FCFM). Our results suggested that the distribution of m-NCs 
within tumor vasculature changed dramatically, but in a reversible way, upon application and 
removal of a magnetic field. The m-NCs were concentrated and stayed as clusters near a 
blood vessel wall when tumors were exposed to a magnetic field but without rupturing the 
blood vessel. The obtained FCFM images provided in vivo in situ microvascular observations 
of m-NCs upon magnetic targeting with high spatial resolution but minimally invasive 
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surgical procedures. This proof-of-concept descriptive study in mice is envisaged to track and 
quantify nanoparticles in vivo in a non-invasive manner at microscopic resolution. 
 
Keywords: Superparamagnetic iron oxide nanoparticles (SPIONs), Magnetic drug targeting, 
Cellvizio®, Tumor, Nanomedicine 
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1. Introduction 
Magnetic drug targeting has been shown to be a promising method of concentrating 
therapeutic agents at a target site, and allowing higher drug doses to be administered while 
still being tolerated by patients .[1-3] A number of studies have demonstrated that magnetic 
nanoparticles (MNPs) can be magnetically targeted to tumor sites and the targeting effect has 
been assessed by various techniques, including optical imaging, magnetic resonance imaging 
(MRI) and histology studies (Prussian blue staining).[4-11] These studies have suggested that 
a higher concentration of magnetic therapeutic agents can be achieved upon the application of 
an external magnetic field. However, the magnetic behaviors of MNPs in blood vessels and 
tumor microcirculation have not been demonstrated. The previously employed imaging 
methods cannot offer sufficient resolution to show how MNPs travel through blood vessels 
and accumulate in tumors, whereas histological studies can only provide ex vivo information 
at post-mortem in a non-dynamic way. Some studies have been carried out using ex vivo 
artery models or mathematical simulation to characterize the MNPs behaviors in blood 
vessels and/or surrounding tissues, but no in vivo studies have been performed so far.[12-15]  
Here we visualized the magnetic capture of m-NCs within blood vessels and tumor tissues in 
real-time in vivo before, during and after magnetic field exposure. The magnetic targeting 
efficacy of m-NCs was firstly quantified by gamma counting and this was further confirmed 
by direct imaging of the magnetic targeting process in blood vessel on the microscopic scale. 
This proof-of-concept descriptive study in mice is envisaged to track and quantify 
nanoparticles in vivo in a non-invasive manner with microscopic resolution. 
 
 
2. Material and methods 
 
2.1 Material 
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‘Ferrofluid’ magnetic oil (oleic acid coated SPIONs with diameter of 10 nm, suspended in 
kerosene at 10
17
 particles per ml) was purchased from Magnacol Ltd (UK). Soybean lecithin 
(Epikuron 140 V) was a kind gift from Cargill Pharmaceuticals (USA). Polyoxyethylene-bis-
amine (NH2-PEG3.5kDa-NH2) was purchased from JENKEM (USA). D/L-lactide/glycolide 
copolymer 75/25 (PLGA18kDa-COOH) was purchased from Purac Biomaterials (the 
Netherlands). Tween
®
 80, nitric acid, methanol, dimethylsulphoxide (DMSO) and 
dichloromethane were obtained from Fisher Scientific Ltd (UK). Fluorescein isothiocyanate–
dextran (FITC-Dextran, average molecular weight 2,000 kDa), sodium chloride, diethylene 
triamine pentaacetic acid (DTPA), castor oil, ethylenediaminetetraacetic acid disodium salt 
dehydrate (EDTA) and Sephadex® G-75 were purchased from Sigma Aldrich (UK). 1,1-
dioctadecyltetramethyl indotricarbocyanine Iodide (DiR) was obtained from Cambridge 
Bioscience (UK). Advanced RPMI-1640 media, penicillin-streptomycin 100X, 0.25 % 
Trypsin-EDTA with phenol red, Glutamax™ supplement, phosphate buffered saline PBS 
(10X, pH 7.4) and phosphate buffered saline PBS (1X, pH 7.4) were obtained from Gibco, 
Invitrogen (UK). Fetal bovine serum (FBS) was obtained from First-Link Ltd (UK). 
Pentobarbital sodium (Euthatal
®
) was obtained from Merial (UK). PD-10 desalting column 
was obtained from GE Healthcare Life Sciences (UK). 
 
2.2 Preparation and characterization of m-NCs and m-NC-DiR 
The magnetic polymeric nanocapsules (m-NCs) were prepared by single 
emulsification/solvent evaporation method.[1] PLGA18kDa-PEG3.5kDa-NH2 and PLGA18kDa-
PEG3.5kDa-DTPA were synthesized as described in our previous work.[16, 17] Briefly, 
PLGA18kDa-PEG3.5kDa-NH2 (12.5 mg, 10% w/w PLGA18kDa-PEG3.5kDa-DTPA was 
incorporated for m-NCs to be used for radiolabeling), castor oil (75 mg), soybean lecithin (25 
mg) and increasing amounts of SPIONs (0, 0.5, 2.5 or 10 mg) were dissolved in 2.5 ml 
dichloromethane. DiR was incorporated into m-NCs formulation at 0.5% w/w DiR/castor oil 
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for fibered confocal fluorescence microscopic (FCFM) imaging. The organic phase was 
poured into an aqueous phase (5 ml) containing Tween
®
 80 (20 mg) as a hydrophilic 
surfactant. The resultant dispersion was emulsified by ultra-sonication using a probe 
sonicator (Soniprep 150, UK) at 15 micro amplitude for 180 s in an ice bath. Organic solvents 
were then evaporated in a chemical fume hood for 20 min. The final volume of the m-NC 
suspension was adjusted to 5 ml. The obtained m-NC suspension was further condensed by 
10 (FCFM imaging) or 20 times (gamma counting), with rotary evaporator, yielding 25 and 
50 mg/ml of polymer, respectively.  
 
2.3 Size and zeta potential measurements 
The hydrodynamic size (Z-Average), polydispersity index (PDI) and zeta potential of NCs 
and m-NCs were determined by NanoZS (Malvern Instrument, UK) at 25 °C using disposable 
square polystyrene cuvettes (for size and PDI) or disposable capillary cells (for zeta potential) 
(Malvern Instrument, UK). The Z-Average diameter and polydispersity index were measured 
in water and presented as the average value of three measurements, with 15 runs within each 
measurement. The zeta potential was also measured in water and presented as the average 
value of three measurements, with 20-25 runs within each measurement. The mean and 
standard deviation (SD) of size and zeta potential were calculated for each sample. 
 
2.4 Determination of SPION encapsulation efficiency in m-NCs 
m-NCs were prepared with increasing loadings of SPIONs (0, 0.38, 1.84 and 7.02 % w/w 
SPION/NC) and purified by size exclusion chromatography (Sephadex® G-75 column, size 
exclusion chromatography) to remove any un-encapsulated SPIONs. The Fe content was 
determined by inductively couple plasma mass spectrometry (ICP-MS, Perkin Elmer SCIEX 
ICP mass spectrometer, ELAN DRC 6100, USA). For ICP-MS measurements, Fe standards 
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(Leeman Labs Inc., USA) were prepared in 20 % nitric acid to obtain a standard curve in the 
range of 10-10000 parts per billion with respect to Fe. m-NCs were digested in 2 ml of nitric 
acid in Falcon™ 15mL conical centrifuge tubes (Fisher Scientific, UK) and incubated 
overnight at 50 °C. The resulting solution was diluted by 10 times with water before the 
measurements.  
 
2.5 Determination of DiR encapsulation efficiency in m-NCs 
The encapsulation efficiency of DiR in m-NCs was assessed using a UV/fluorescence 
spectrometer (Varian, Cary Eclipse, Australia). Prior to quantification, m-NC-DiR 
suspensions were purified by a PD-10 desalting column (size exclusion chromatography) and 
eluted in PBS buffer to remove any free DiR. The m-NC suspensions before and after 
purification were diluted in DMSO (1/19, v/v) to rupture the NC structure. The 
excitation/emission wavelengths for the detection of DiR were 740/785 nm. The 
encapsulation efficiency was expressed as the percentage of the encapsulated dye to the total 
amount of DiR added to the formulation. All measurements were performed in triplicate and 
expressed as mean ± SD (n=3). 
 
2.6 Radio-labelling of m-NCs and serum stability studies 
To radio-label the m-NCs with indium-111, m-NCs were prepared as described in the 
previous section except that PLGA18kDa-PEG3.5kDa-DTPA was included at 10 % (w/w) of the 
total polymer content. The m-NC suspension (250 µL, 50 mg/mL of polymer) was incubated 
with 2 M ammonium acetate (one ninth of the reaction volume, pH 5.5), to which 1 MBq of 
111
InCl3 (Mallinckrodt, UK) was added for gamma counting. The reaction was kept at room 
temperature for 30 min with intermittent vortexing every 10 min. Upon completion, the 
radio-labelling reaction was quenched by the addition of 0.1 M EDTA chelating solution (one 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
    
 7 
twentieth of the reaction volume). 
111
InCl3 alone was subjected to the same labelling reaction 
conditions and used as a control. 
The m-NC-
111
In was passed through PD-10 columns before injecting into animals to 
exchange the ammonium acetate buffer (pH 5.5) with PBS (pH 7.4) and remove free 
111
In-
EDTA. The m-NCs-
111
In (~150 µL per injection dose, 25 mg/mL of polymer) were collected 
from the column and spotted on instant thin layer chromatography (iTLC) strips which were 
then developed in 0.1 M ammonium acetate containing 50 mM EDTA as a mobile phase. 
Strips were allowed to dry before being developed and counted quantitatively using a cyclone 
phosphor detector (Packard Biosciences, UK) to ensure no free 
111
In-EDTA present in the 
injected solution.  
 
2.7 Animal studies and tumor inoculation 
All animal experiments were performed in compliance with the UK Home Office (1989) 
Code of Practice for the Housing and Care of Animals used in Scientific Procedures. CT26 
murine colon carcinoma cells (CT26, ATCC®, CRL-2638TM) were cultured in Advanced 
RPMI (Roswell Park Memorial Institute) 1640 medium supplemented with 1% L-glutamine, 
1% penicillin-streptomycin and 10% fetal bovine serum (FBS), in 5 % CO2 and 95 % air, at 
37 °C.  The harvested CT26 cells were suspended in PBS solution (pH 7.4). A total of 1×10
6
 
cells in 20 µL were injected subcutaneously and bifocally at the hind foot of female BALB/c 
mice aged 4-6 weeks (Harlan, UK). After inoculation, the tumor volume was measured on 
day 8 and then every other day using a digital caliper and calculated using Equation (1) [2] 
Tumor volume (mm
3
) = (4/3) * π (A/2)2 *(B/2) =0.52A2B        (1) 
where A and B represent the width and the length of the tumors, respectively. All experiment 
were carried out (m-NCs administration) when the tumor volume reached approximately 500 
mm
3
. 
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2.8 Magnetic targeting setup in vivo 
Disk-shaped nickel-coated neodymium iron boron (Nd2Fe14B) magnets (Magnet Expert Ltd, 
Tuxford, UK) were used for the in vivo magnetic drug targeting studies. That was an 8 mm 
diameter, 5 mm thick, N42 grade magnet (product code F324), which had a reported field 
strength of 0.43 Tesla (T) and a reported ‘vertical pull’ parameter (a measure of the mass of 
material that the magnet could lift) of 1.9 kg. Single magnet was placed non-invasively over 
the surface of one of the bifocal tumors and retained using surgical tapes. The contralateral 
tumor was used as an internal negative control where no magnet was applied. The magnet 
was then removed at 1 h post-injection of m-NCs.   
 
2.9 Fibered confocal fluorescence microscopic imaging studies 
The visualization of m-NCs in tumor vasculature in vivo upon the application of a magnetic 
field was performed using a fibered confocal fluorescence microscopy (FCFM) imaging 
system (Cellvizio®, Mauna Kea Technologies, Paris, France). CT26 tumor-bearing BALB/c 
mice were injected via the tail vein with m-NC-DiR with a SPION content of 125 mg/kg and 
DiR content of 9.4 mg/kg (corresponding to 312.5 mg polymer/kg). FITC-Dextran (MW 
2,000 kDa, 500 mg/kg, 150 µL) was injected intravenously immediately prior to FCFM 
imaging to visualize the microvascular network. A small incision (~0.5 cm) was made to 
insert the laser probe. The exposed tissues were kept moist with PBS pre-warmed to 37 °C. 
During the time of acquisition, mice were placed in the prone position (tumor and muscle) or 
supine position (liver) and anesthetized with 1.5 % isoflurane/98.5 % oxygen. Body 
temperature was controlled by a probe-coupled heating mat. Images and videos were 
acquired using an S-1500 probe with a penetration depth of 15 µm below tissue surface. To 
image m-NCs in the tumor vasculature upon exposure to a magnetic field in real-time, a set of 
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magnets (10 disc magnets, 0.43 T, product code F324, Magnet Expert Ltd, Tuxford, UK) was 
placed adjacent to the surgical incision for 10 min.. FCFM imaging was performed before, 
during and after application of a magnetic field. Extravasation of the m-NCs through blood 
vessel wall and accumulation over time were also assessed in tumor (TU+ and TU-), 
quadriceps femoris muscle and liver at 1, 4 and 24 h post-injection. All imaging was carried 
out using a frame rate of 9 Hz (full FOV), a field of view of 618 × 609 µm and 100 % laser 
power at 488 and 660 nm. Images and videos were analyzed using Cellvizio® dual viewer 
(Mauna Kea Technologies, Paris, France) and videos were reconstructed using ImageJ 
software. 
 
2.10 Assessment of blood circulation, organ biodistribution and tumor accumulation profiles 
of m-NCs by gamma counting 
Blood circulation, organ biodistribution and tumor accumulation profiles of m-NC-
111
In with 
increasing SPION contents (0, 5, 25 and 125 and 500 mg/kg), representing m-NC-5, m-NC-
25, m-NC-125, m-NC-500, respectively, were assessed quantitatively in CT26 tumor-bearing 
BALB/c mice using gamma counting. Mice were injected intravenously via tail vein with 
~0.7 MBq m-NC-
111In (150 μL in PBS). Magnetic targeting was applied as described in 
supplementary information. Blood samples (5 μL) were collected from the tail vein at 10 min, 
30 min, 1 h, 4 h and 24 h post-injection. Liver, spleen, magnetically-targeted tumors (TU+) 
and non-magnetically targeted tumors (TU-) were excised and weighed. The radioactivity 
was measured by a gamma counter (1280 CompuGamma Universal Gamma Counter, LKB 
Wallac, Finland), using the appropriate energy windows for 
111
In. Results were expressed as 
percentage of injected dose (% ID) in blood or per gram organ or tumor (% ID/g) as means ± 
SEM (standard error of the mean) (n=3).  
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2.11 Statistics Statistical Analysis 
All statistical tests were performed using IBM SPSS version 20. The significance (p-value) 
was determined. One-way ANOVA was performed using IBM SPSS Statistics 20 software 
followed by Tukey’s multiple comparison test using Origin 8.6 software. When p-values 
were 0.05 or less, differences were considered statistically significant. 
 
3. Results and discussion 
3.1 Preparation and characterization of magnetic nanocapsules (m-NCs) 
We designed a magnetic nanocapsule system (m-NCs) encapsulating a high amount of 
superparamagnetic iron oxide nanoparticles (SPIONs) which enables successful magnetic 
drug targeting in vivo. The m-NCs were designed in such a way that they can be imaged with 
optical imaging (due to DiR incorporation), MR imaging (due to SPION) and nuclear 
imaging (by chelation of radioactive indium-111 (
111
In) to diethylene triamine pentaacetic 
acid (DTPA) conjugated to the polymer). These triple-labeled m-NCs combined with imaging 
techniques such SPECT/CT and fibered confocal fluorescence microscopy allowed us to 
examine the kinetics of m-NCs accumulation/extravasation in mice organs, including tumors, 
on a microscopic scale when an external magnetic field was applied.  
PEGylated oil-cored polymeric magnetic nanocapsules (m-NCs) were prepared using a single 
emulsification/solvent evaporation method.[16] m-NCs of increasing SPION loadings: 0%, 
0.4%, 1.8% and 7% w/w SPION/NC were prepared affording NC, m-NC-25, m-NC-125 and 
m-NC-500, respectively, were prepared. DiR/SPION encapsulation efficiency (%EE), 
hydrodynamic sizes (200 to 220 nm) and zeta potentials (- 30 to - 45 mV) are summarized in 
Table 1 and Table 2.  
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Table 1. Physicochemical characterization of PEGylated NCs and m-NCs prepared by a 
single emulsification/solvent evaporation method 
Formulation[a] 
Hydrodynamic size 
(nm)[b],[e] 
PDI [b],[e] 
Zeta potential 
(mV)[c],[e] 
DiR 
EE%[d],[e] 
NC 203 ± 4 0.12 ± 0.01 -45 ± 2 - 
m-NC 205 ± 3 0.16 ± 0.01 -36 ± 1 - 
NC-DiR 206 ± 5 0.16 ±0.01 -39 ± 2 99 ± 4 
m-NC-DiR 209 ± 2 0.19 ±0.02 -32 ± 1 95 ± 5 
[a] Formulations were prepared with a SPION content of 1.85% w/w SPION/NC 
[b] Values were measured with dynamic light scattering and measured in deionized water 
[c] Values were obtained with laser Doppler electrophoresis and measured in deionized water 
[d] Values were determined by fluorescence spectroscopy 
[e] Results are expressed as mean ± SD (n=3) 
 
 
Table 2. Physicochemical characterization of PEGylated NCs with different SPION loadings 
prepared by a single emulsification/solvent evaporation method. 
Formulation 
Hydrodynamic 
size (nm)
[a],[e]
 
PDI
[a], [e]
 
Zeta potential
 
(mV)
[b], [e]
 
SPION 
EE%
[c], [e]
 
Initial SPION 
loading (% 
w/w, 
SPION/NC)
[d]
 
Final SPION 
loading (% w/w, 
SPION/NC)
[d], [e]
 
NC 203 ± 4 0.12 ± 0.01 -45 ± 2 - 0.00 0.00 
m-NC-25 218 ± 4 0.17 ± 0.02 -39 ± 1 99 ± 2 0.38 0.38 ± 0.01 
m-NC-125 205 ± 3 0.16 ± 0.01 -36 ± 1 95 ± 3 1.85 1.76 ± 0.06 
m-NC-500 214 ± 9 0.19 ± 0.02 -31 ± 1 94 ± 9 7.02 6.60 ± 0.63 
[a] Size was measured with dynamic light scattering and measured in deionized water 
[b] Values were obtained with laser Doppler electrophoresis and measured in deionized water 
[c] Iron content was determined by ICP-MS 
[d] Weight of NCs includes polymer, lecithin, castor oil, SPION and tween 80®. Initial and final loading refers 
to SPION content before and after size exclusion chromatography. 
[e] Results are expressed as mean ± SD (n=3) 
 
3.2 The correlation between blood circulation time of m-NCs and tumor accumulation under 
passive and magnetic targeting conditions  
We firstly assessed the blood circulation time, reticuloendothelial system (RES) organs, and 
tumor accumulation of m-NCs with an increasing amount of SPIONs in vivo in the presence 
(TU+) or absence (TU-) of a magnetic field in a subcutaneous CT26 (murine colon 
carcinoma) tumor model. These m-NCs were radio-labeled with 
111
In and their concentrations 
in blood and tumors were measured by gamma counting. Figs. 1a and b show the percentage 
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injection dose (% ID) of m-NCs accumulated in the tumor (+/- magnetic field) against the 
amount remaining in blood at 4 h. Non-magnetic NC, m-NC-5, m-NC-25, m-NC-125 showed 
comparable blood circulation time with the exception of m-NC-500 which exhibited 
significantly shorter blood circulation time. A linear relationship (r
2
 = 0.8650) between % 
ID/g tumor and % ID in blood was shown in the absence of a magnetic field, i.e. TU- (Fig. 
1a). The good correlation between these two parameters indicates that passive tumor 
accumulation was dependent on the blood concentration of m-NCs, as reported in the 
literature.[18] On the other hand, this linearity could not be achieved when a magnetic field 
was applied, i.e. TU+. This suggests that the magnetic force was able to influence the tumor 
uptake. Fig. 1c shows the %ID/g in RES organs, e.g., liver and spleen. The high uptake of m-
NC-500 in both organs corresponded well to the reduced blood circulation time and 
contributed to its low TU- accumulation. 
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Fig. 1 Organ biodistribution studies of m-NC-111In in CT26 tumor-bearing BALB/c mice 
under the influence of a magnetic field. Mice were intravenously injected with NC-111In or 
m-NC-111In at SPION content of 25, 125 and 500 mg/kg. Blood samples were collected at 
specified time points and organs and tumors were excised at 24 h post-injection. Scatter plots 
of %ID of m-NCs in tumor tissue (24 h) without (a) or with (b) magnetic targeting as a 
function of blood concentration (4 h). The best-fit linear regression line along with the 95% 
confidence band is shown with a correlation coefficient (r2) of 0.8650 in tumor tissue without 
magnetic targeting (TU-). (c) Liver and spleen accumulation profiles of m-NC-111In with an 
increasing amount of SPION. Results are expressed as % ID/g of organ as mean ± SEM 
(n=3). One-way ANOVA was performed using IBM SPSS version 20 followed by Tukey’s 
multiple comparison test (**p < 0.01). 
 
3.3 Live fibered confocal fluorescence microscopic imaging of m-NCs in tumor blood vessel 
under the influence of a magnetic field 
The investigation of the effect of magnetic forces on m-NC accumulation kinetics in the 
tumor vasculature is limited by the imaging resolution and invasiveness. As a result, to 
visualize it dynamically on a microscopic vascular level, a fibered confocal fluorescence 
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microscopy system (FCFM, Cellvizio®, Mauna Kea Technology, Paris, France) was used in 
this study. Non-magnetic NCs (used as a negative control) and m-NCs were fluorescently 
labeled with DiR as an optical probe. Fluorescein isothiocyanate–dextran (FITC-Dextran), 
used as a vascular contrast agent, remained in the blood vessels and no leakage up to 1 h has 
been reported. Mice were inoculated bi-focally with subcutaneous tumors. The imaging probe 
was inserted into the tumors via a small incision and tissues were kept moist throughout the 
experiment. The imaging protocol is schematically presented in Fig. 2. m-NCs were injected 
at 0 h and a magnetic field was then applied to one tumor for 1 h. Multiple imaging was 
performed at 1,4 and 24 h.  
 
Fig. 2 Experimental timeline of fibered confocal fluorescence microscopic (FCFM) 
imaging of m-NCs in tumor vasculature under the influence of a magnetic field (MF). 
CT26 tumor-bearing BALB/c mice were injected intravenously with m-NC-DiR and a 
magnet was applied only at one of the bifocal tumors (TU+) for 1 h. FCFM imaging was 
performed at 1, 4 and 24 h post-injection in both TU+ and TU-. Non-previously injected 
mouse was used for each time point. FITC-Dextran was injected intravenously at a dose of 
500 mg/kg prior to each imaging time point as a macromolecular contrast agent. Inset (top) 
shows the dynamic FCFM imaging of m-NCs in tumor blood vessels during MF application 
to demonstrate the interaction of m-NCs and MF on a microscopic scale.   
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Prior to application of a magnetic field, DiR-labeled non-magnetic NCs were observed 
homogenously distributed in blood vessels (Fig. 3a, left panel; Movies 1a-c). The application 
of a magnetic field did not cause any changes in the distribution of non-magnetic NCs within 
the blood vessels. m-NCs, on the other hand, behaved differently when a set of magnets was 
applied in close proximity to the vessels. DiR labeled m-NCs started to magnetize, and those 
magnetized sufficiently appeared as clusters and enriched near the blood vessel wall (Fig. 3a, 
right panel; Movies 1d-f). The m-NC aggregation was reversible upon removal of the 
magnetic field due to the superparamagnetism of m-NCs.[1, 2, 19]
 
More importantly, the 
blood vessels appeared intact with no observation of vessel leakage of FITC-Dextran induced 
by the application of the magnetic field, suggesting no vascular damage per se. The 
enrichment of m-NCs within the tumor microvasculature or further enhanced retention in 
blood vessels would raise the probability of extravasation into the tumor interstitium and 
thereby increasing tumor uptake.  
The m-NC distribution in both U- and TU+ over time was also studied using FCFM. 
Tumors are heterogeneous and contain irregular capillary networks and non-vascularized 
areas of necrosis.[20-22] FCFM imaging was performed focusing on the highly vascularized 
regions. FCFM images showed clear co-localization of FITC-Dextran and m-NC-DiR in 
tumor blood vessels at 1 h and 4 h, confirming the prolonged blood circulation of m-NCs (Fig. 
3b).[16]
 
As expected, DiR signals became more diffuse and spread out throughout the tumor 
interstitium at 24 h. Interestingly, more intensive signals were seen in TU+ compared to TU-, 
suggesting enhanced tumor accumulation upon magnetic targeting, consistent with our 
previously published work.[16] 
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Fig. 3 Live fibered confocal fluorescence microscopic (FCFM) images of m-NCs in 
tumor tissues. m-NC-DiR were injected intravenously into CT26 tumor-bearing BALB/c 
mice and imaged with FCFM using FITC-Dextran as the vascular contrast agent. (a) Real-
time FCFM imaging of fluorescently labeled non-magnetic NC (NC-DiR) or magnetic NC 
(m-NC-DiR) (red signals) in tumor blood vessels (green signals) with an external magnetic 
field (MF) applied at the external part of tumor (TU+), for both formulations. Dashed circle 
shows the magnetized m-NC-DiR, and not NC-DiR is concentrated in the blood vessels upon 
the application of a magnetic field. (b) Representative single frame FCFM images of m-NC-
DiR in non-magnetically targeted tumors (TU-) and magnetically targeted tumors (TU+) at 1, 
4 and 24 h post-injection. All images were acquired using the Cellvizio® dual band imaging 
system. Please refer to the videos (supplementary information) for clearer targeting pattern.  
Scale bar is 50 um. 
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3.4 Real-time fibered confocal fluorescence microscopic imaging of m-NCs extravasation in 
healthy tissues 
The extravasation of m-NCs were also assessed in healthy tissues to validate the usefulness 
for real-time nanoparticle imaging. Muscle and liver which exhibit distinct vascular 
characteristics were used as examples.[23]
 
Fig. 4 (left panel) shows muscle blood vessels. No 
DiR signal was visible in the blood vessels of muscle tissues at 24 h, in contrary to the 1 h 
time point where m-NCs were seen in the vasculature. This is consistent with m-NC 
distribution data, where no m-NC retention was seen in muscle at 24 h, due to the continuous 
capillaries and complete basement membrane.[16, 24, 25]
 
 It was also confirmed that DiR 
labeling was confined to the m-NCs and the dye did not translocate to cellular membrane. In 
contrast, a number of m-NCs leaked out of the liver sinusoids and accumulated in non-
vascular liver tissues at 24 h (Fig. 4, right panel), consistent with gradual liver accumulation 
over time described in our previously published work.[16]
 
This was not surprising as the liver 
vasculature has an incomplete basement membrane and transcytoplasmic openings.[25] 
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Fig. 4 Real-time fibered confocal fluorescence microscopic (FCFM) images of m-NCs in 
muscle and liver. m-NC-DiR were injected intravenously into CT26 tumor-bearing BALB/c 
mice and imaged with FCFM using FITC-Dextran as the vascular contrast agent. 
Representative single frame FCFM images of m-NC in muscle and liver tissues at 1, 4 and 24 
h post-injection with the application of a magnetic field at the tumor. All images were 
acquired using the Cellvizio® dual band imaging system. Scale bar is 50 um. 
 
It is conceivable from experimental physics and prior knowledge that magnetic nanoparticles 
(MNPs) can be attracted by the magnetic forces in tumour blood vessel and be concentrated 
to the tumour tissue. A number of studies indeed have demonstrated that MNPs could be 
concentrated in the tumour under the influence of a magnetic field by MRI [5, 11]. However, 
MRI cannot provide sufficient resolution to image the MNP in tumour vasculature. Whether 
or not the magnetic forces acting on individual m-NC is strong enough to overcome blood 
flow has not been addressed. A direct visualisation in a time-course study is required.  
The FCFM provides real-time in vivo microvascular observations and in situ high spatial 
resolution imaging (up to 1.4 µm) at vascular level. It also represents a significant advantage 
over traditional intra-vital microscopic imaging (IVM) which usually requires invasive 
surgical procedures and is limited by the availability of animal models that bear visually 
accessible tumours in a dorsal skinfold chamber. FCFM enables micro-invasiveness and 
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requires only a small incision at the imaging site. Small openings can be sutured if the 
animals are required to be kept for long-term studies.  
 
4. Conclusion 
A number of studies have explored magnetic targeting in drug delivery. However, this is the 
first report of real-time live imaging of magnetic targeting in tumor vasculature on the 
microscopic scale. The novel application of FCFM described in this study offers direct 
visualisation of m-NCs within blood vessels and in tumour tissues before, during and after 
magnetic field exposure in a real-time manner, with high resolution and minimal surgical 
intervention. Our results suggested that the distribution of m-NCs within tumour vasculature 
changed dramatically, but in a reversible way, upon application and removal of a magnetic 
field. The m-NCs were concentrated and stayed as clusters near a blood vessel wall when 
tumours were exposed to a magnetic field but without rupturing the blood vessel. This work 
bridges the gap between previous findings of enhanced tumor uptake with magnetic targeting 
and the nanocarrier behavior at the blood-tumor vasculature-tumor tissue interface, thanks to 
the high resolution characteristics of this imaging modality. This proof-of-concept descriptive 
study in mice is envisaged to track and quantify nanoparticles in vivo in a non-invasive 
manner with microscopic resolution. 
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